CFO
RNAM

CVA Family Office’s Avidity Biosciences RNAM Stock Holding History

CVA Family Office’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$590 – 1423
2025
Q1 		$590 Hold
20
– – ﹤0.01% 1194
2024
Q4 		$582 Hold
20
– – ﹤0.01% 1189
2024
Q3 		$919 Hold
20
– – ﹤0.01% 1088
2024
Q2 		$817 Buy
+20
New +$574 ﹤0.01% 1102

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CVA Family Office's RNAM Position: Q2 2025 in Review

CVA Family Office sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 20 shares — an estimated $590 sold.

CVA Family Office first reported a position in RNAM in Q2 2024 and held it in 4 quarters. The position peaked at $919 in Q3 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • CVA Family Office reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • CVA Family Office sold 20 Avidity Biosciences shares in Q2 2025, an estimated $590.
  • CVA Family Office first reported a position in Avidity Biosciences in Q2 2024 and held it in 4 quarters.
  • CVA Family Office's Avidity Biosciences position peaked at $919 in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on CVA Family Office's 13F filing for Q2 2025, filed 31 Jul 2025.